Introduction {#section1-2041731420901621}
============

Adequate *in vitro* biomaterial testing is vital for predicting the success of a biomaterial *in vivo.* Therefore, a significant amount of research is underway to screen biomaterials prior to pre-clinical *in vivo* animal testing, which is considered a prerequisite for clinical studies.^[@bibr1-2041731420901621],[@bibr2-2041731420901621]^ It is well established that significant inconsistencies exist between predicted outcomes of biomaterials tested *in vitro* and their actual performance *in vivo.* A focus of current research is to establish models that could bridge the gap between *in vitro* testing and *in vivo* outcomes in accordance with the principles of NC3Rs (National Committee for Reduction, Refinement and Replacement of Animals).

Recently, chorioallantoic membrane (CAM) assays of the chick embryo are gaining wide popularity as they are a cost-effective and less sentient '*in vivo*' model for biomaterial testing.^[@bibr3-2041731420901621]^ The primary reason for this is that the CAM is highly vascularised, constituting both mature vessels and capillaries, and is easily accessible for orthotopic implantation of biomaterials without initiating an immune reaction from the developing embryo. The gestation period of a chick embryo is 21 days, with the CAM formed around embryonic day (ED) 4 following the fusion of the allantois and the chorion membrane. The function of this membrane is to provide gaseous exchange between the developing embryo and the eggshell pores, and allow ion and nutrient exchange.^[@bibr4-2041731420901621]^ The capillary bed of the CAM is non-innervated and has been used in the field of tissue engineering for over four decades to study graft versus host reactions.^[@bibr5-2041731420901621],[@bibr6-2041731420901621]^

In 2006, the US Food and Drug Administration (FDA) approved CAM models for pre-clinical evaluation of products used for the treatment of chronic cutaneous wounds.^[@bibr7-2041731420901621]^ More recently, CAMs have been used to perform anti-angiogenic studies in cancer research and for assessing the angiogenic behaviour of biomaterials under development for tissue engineering applications.^[@bibr8-2041731420901621],[@bibr9-2041731420901621]^ CAMs can be used in an *in ovo* or *ex ovo* form for studying angiogenesis.^[@bibr10-2041731420901621][@bibr11-2041731420901621][@bibr12-2041731420901621]--[@bibr13-2041731420901621]^ *In ovo* CAM assays are very popular, but due to the lack of standardisation, a significant amount of variation exists in the technique. Moreover, the *in ov*o approach is inefficient in maintaining sterility and often results in contamination from the eggshell dust. Recent advancements in *ex ovo* culture techniques have resulted in the development of an efficient, reproducible, and cost-effective assay that is slowly gaining popularity for testing angiogenesis in biomaterials.^[@bibr13-2041731420901621],[@bibr14-2041731420901621]^

A wide variety of biomaterials with different structures and compositions are being developed at a rapid pace to address various unmet clinical needs. Varying structure and composition can have a large effect on function -- at the extremes resulting in successful outcomes with tissue repair and regeneration or in failed outcomes with no tissue repair or biomaterial rejection.^[@bibr15-2041731420901621],[@bibr16-2041731420901621]^ Critical to the repair process in many therapeutic applications is the restoration of blood vessels, to supply nutrients and oxygen to the damaged tissue. The porous structure of a biomaterial plays a key role in biomaterial revascularisation. However, the extent to which other parameters, such as composition and mechanical properties, also affect biomaterial revascularisation is still not clear.^[@bibr16-2041731420901621],[@bibr17-2041731420901621]^ Composition here refers to the material the scaffold is composed of and not its surface roughness, crystallinity and surface energy. Oates et al, utilised the *in ovo* CAM assays to demonstrate how specific material characteristics such as porosity and pore size could affect a biomaterial's intrinsic angiogenic potential.^[@bibr18-2041731420901621]^ Other studies have also shown that changing the structure and composition of a biomaterial directly affects its angiogenic potential, for example, crosslinked collagen matrices with a high average pore size and a rigid structure show a significantly higher angiogenic potential compared to non-crosslinked polymers.^[@bibr19-2041731420901621],[@bibr20-2041731420901621]^ The chemical composition of smooth materials such as Tecoflex^®^, which is a medical-grade aliphatic polyether polyurethane and polyvinylchloride (PVC), has previously been shown to induce an anti-angiogenic response, whereas rough materials such as filter paper and collagen/elastin membranes have been shown to induce an angiogenic response. ^[@bibr10-2041731420901621]^ These studies suggest that the extent of angiogenic response of a biomaterial *in vivo* is dependent on multiple factors but mainly depends on porosity and the composition. Therefore, it is vital to pre-screen biomaterials under development using methods that mimic the *in vivo* situation as closely as possible.

While the *in ovo* CAM assay is popular, only a handful of studies have used the *ex ovo* method for biomaterial testing ^[@bibr3-2041731420901621],[@bibr13-2041731420901621],[@bibr21-2041731420901621][@bibr22-2041731420901621]--[@bibr23-2041731420901621]^ The aims of this study were (1) to optimise the previously reported *ex ovo* CAM assays using a glass-cling film set-up and (2) to report the suitability of this method in screening biomaterials to select candidates for further development by examining the angiogenic capacity of a range of biomaterials.

Materials and methods {#section2-2041731420901621}
=====================

Fabrication of biomaterials {#section3-2041731420901621}
---------------------------

Biomaterials used in this study were categorised as natural, synthetic, natural/synthetic and natural/natural ([Figure 1](#fig1-2041731420901621){ref-type="fig"}). These were ([Table 1](#table1-2041731420901621){ref-type="table"}) (1) three-dimensional (3D) porous collagen matrix, fabricated using 90% collagen type I (FirstLink, Wolverhampton, UK) and 10% Minimum Essential Medium (MEM; Invitrogen, Paisley, UK). This solution was neutralised by 5 M NaOH and crosslinked with 0.25% glutaraldehyde; (2) 3D crosslinked porous matrix of bovine fibrin, fabricated using 2% bovine fibrinogen in phosphate-buffered saline (PBS) and 10% thrombin, crosslinked with 0.25% glutaraldehyde; (3) 3D crosslinked porous matrix of elastin, fabricated from 10% (v/v) of the elastin powder (Sigma, Dorset, UK) mixed with 1 mL of 0.5 M oxalic acid (freshly prepared) at room temperature and crosslinked with 2.5% glutaraldehyde; (4) electrospun poly-ɛ-caprolactone (PCL), commercially purchased from The Electrospinning Company Ltd. (Didcot, UK) (micro-PCL); (5) electrospun PCL, fabricated in Professor Maria A. Woodruff's lab using the methods described in Ristovski et al.^[@bibr24-2041731420901621]^ (macro-PCL); (6) silicone, purchased from BITY Mould Supply (Richardson, TX, USA); (7) commercially available dermal replacement scaffold Integra^®^, a 3D crosslinked porous matrix made of bovine tendon collagen type I with 10%--15% chondroitin-6-sulphate from shark cartilage and a silicone backing layer (Integra Life Science Corporation, Plainsboro, NJ, USA); (8) electrospun PCL and 3D porous matrix of bovine fibrin (PCL/Fib) composite scaffolds fabricated using micro-PCL and coated with fibrin; (9) electrospun PCL and collagen (PCL/Col) scaffold fabricated using micro-PCL and coated with neutralised collagen; (10) 3D crosslinked porous matrix made of bovine fibrin and alginate, developed in our laboratory; (11) commercially available dermal replacement scaffold Matriderm^®^, a 3D porous matrix of bovine collagen types I, III and V, and elastin hydrolysate (MedSkin Solutions, Billerbeck, Germany); and (12) demineralised bone matrix (DBM) clinically available and supplied by NHS-BT (Birmingham, UK).

![Representative stereo microscope images of the biomaterials tested.The stereo microscopic images show the overall structure of the biomaterials tested, highlighting the differences in their architecture. Macroscopically, each biomaterial appears intact and ranges in appearance from fibrous to porous matrices, except silicone which appears as a transparent sheet.](10.1177_2041731420901621-fig1){#fig1-2041731420901621}

###### 

A summary of the biomaterials used in this study with their structural composition and functional properties.

![](10.1177_2041731420901621-table1)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                              Composition                                                                                                                                                 Application                             Development phase
  --------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- -------------------
  Collagen                          Natural scaffold\                                                                                                                                           Soft tissue regeneration                Pre-clinical
                                    3D crosslinked porous matrix of collagen type I from rat tail tendon                                                                                                                                

  Fibrin                            Natural scaffold\                                                                                                                                           Soft tissue regeneration                Pre-clinical
                                    3D crosslinked porous matrix of bovine fibrin                                                                                                                                                       

  Elastin                           Natural scaffold\                                                                                                                                           Soft tissue regeneration                Pre-clinical
                                    3D crosslinked porous matrix of elastin from bovine ligament                                                                                                                                        

  Micro-PCL                         Synthetic scaffold\                                                                                                                                         Soft tissue regeneration                Pre-clinical
                                    Electrospun PCL                                                                                                                                                                                     

  Macro-PCL                         Synthetic scaffold\                                                                                                                                         Bone regeneration                       Pre-clinical
                                    Electrospun PCL                                                                                                                                                                                     

  Silicone                          Synthetic scaffold\                                                                                                                                         Epidermal component of skin scaffolds   In clinical use
                                    Platsil 73-15 Precision Silicone                                                                                                                                                                    

  Integra^®^                        Natural and synthetic composite scaffold\                                                                                                                   Repair of full-thickness skin wounds    In clinical use
                                    3D crosslinked porous matrix made of bovine tendon collagen type I with 10%--15% chondroitin-6-sulphate from shark cartilage and a silicone backing layer                                           

  PCL/Fib                           Natural and synthetic composite scaffold\                                                                                                                   Soft tissue regeneration                Pre-clinical
                                    Electrospun PCL and 3D porous matrix of bovine fibrin                                                                                                                                               

  PCL/Col                           Natural and synthetic composite scaffold\                                                                                                                   Soft tissue regeneration                Pre-clinical
                                    Electrospun PCL and 3D porous matrix of collagen type I from rat tail                                                                                                                               

  Fibrin/Alginate                   Natural composite scaffold\                                                                                                                                 Repair of full-thickness skin wounds    Pre-clinical
                                    3D crosslinked porous matrix made of bovine fibrin and alginate                                                                                                                                     

  Matriderm^®^                      Natural composite scaffold\                                                                                                                                 Repair of full-thickness skin wounds    In clinical use
                                    3D porous matrix of bovine collagen types I, III and V, and elastin                                                                                                                                 

  Demineralised bone matrix (DBM)   Type I collagen and non-collagenous proteins                                                                                                                Bone regeneration                       In clinical use
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

3d: three-dimensional; PCL: poly-ε-caprolactone.

Scanning electron microscopy {#section4-2041731420901621}
----------------------------

Biomaterials were mounted on stubs and sputter-coated with carbon coater. All images were obtained using a secondary electron detector in a Philips XL 30 Field Emission scanning electron microscope, operated at 5 kV and an average working distance of 10 mm.

Porosity and pore size analyses {#section5-2041731420901621}
-------------------------------

To calculate percentage porosity and pore size range of scaffolds, scanning electron microscopy (SEM) images were quantitatively analysed using ImageJ bundled with 64-bit Java 1.6.0 (National Institutes of Health (NIH), USA). A threshold frequency was adjusted to visualise all pores. An area fraction function was used for calculating porosity, and particle analysis function was used to determine the diameter of each pore. For porosity, *n* = 3 different scaffolds were used, except for scaffolds with porosity values previously reported in the literature (Integra^®^, fibrin/alginate and DBM). The previously published values may have been calculated using alternate methods of measuring porosity such as histology or mercury intrusion porosimetry. For pore size range, *n* = 3 different SEM images from three different scaffolds were used with over 1000 pores analysed per scaffold to determine the gradient pore structure (GPS) and the frequency of each pore diameter.

*Ex ovo* experimental set-up {#section6-2041731420901621}
----------------------------

We compared two methods in this study: previously published methods using weighing boats for the *ex ovo* set-up and our proposed method called the glass-cling film set-up. For details on the previously published methods, refer to the study by Dohle et al.^[@bibr13-2041731420901621]^

A glass-cling film set-up was used for maintaining the *ex ovo* cultures ([Figure 2](#fig2-2041731420901621){ref-type="fig"}). Pyrex glasses of 8 cm diameter were autoclaved for sterilisation. The glasses were filled up to three-quarters with sterile water and a clean cling film layer (pre-sterilised with 70% industrial methylated spirit (IMS) and dried) was placed inside the glasses ensuring that the bottom of the cling film touched the water. Next, 500 µL of antibiotic, antimycotic solution (Sigma, Dorset, UK) was pipetted onto the cling film at a final concentration of 1 in 100. This solution is referred to as antimicrobial solution (AM solution) in this study. Rubber bands were used to secure the cling film on the glasses.

![A pictorial illustration of *ex ovo* cultures. A step-by-step procedure is shown from incubating the eggs to culturing them *ex ovo*. The proposed glass-cling film set-up is shown detailing the materials required to successfully perform shell-less cultures.](10.1177_2041731420901621-fig2){#fig2-2041731420901621}

*Ex ovo* CAM assays {#section7-2041731420901621}
-------------------

The use of chick embryos in this study did not require ethical approval as per the guidelines of the Institutional Animal Care and Use Committee (IACUC) and the NIH (USA), which states that a chick embryo that has not reached the 14th day of its gestation period would not experience pain and can therefore be used for experimentation without any ethical restrictions or prior protocol approval.^[@bibr25-2041731420901621],[@bibr26-2041731420901621]^ Fertile chicken eggs were purchased from local farms in Middlesex (UK) and incubated in an egg incubator with automatic rotation for 3 days at 38°C and 45%--50% humidity. At day 3, eggs were wiped with cytosol and cracked open using a triangle magnetic stirrer. The contents were immediately transferred to the glass-cling film set-up described above. The yolk sac and the embryo were identified and assessed for viability by looking for a beating heart. To prevent contamination from the egg shells, 500 µL of antimicrobial solution was pipetted gently onto the albumen. The glasses were then covered with a Petri dish and transferred to the incubator and grown for a further 6 days at 38°C and 80%-90% humidity. At day 9, up to six scaffolds (roughly 5 mm × 5 mm in size) were implanted on the CAM as shown in [Figure 3](#fig3-2041731420901621){ref-type="fig"}. Filter discs soaked in vascular endothelial growth factor (VEGF) and PBS were used as positive and negative controls, respectively. After placement of the scaffolds, the *ex ovo* cultures were incubated for a further 3 days.

![An example of biomaterial implantation on the CAM. The contents of the shell-less cultures are imaged from above, showing the embryo, the developing CAM and the different biomaterials at day 9.](10.1177_2041731420901621-fig3){#fig3-2041731420901621}

CAM assay analyses {#section8-2041731420901621}
------------------

At the end of the testing period (ED 12), embryos were euthanised under the British Home Office regulations by freezing at −20°C for approximately 15 min. The CAM was then covered with 5 mL of 4% paraformaldehyde (PFA) for 15 min (to avoid bleeding of CAM after excision). The scaffolds were carefully dissected out with a 5-mm perimeter of the CAM excised along with the scaffold. Images were acquired by inverting the scaffolds to observe infiltrating blood vessels from underneath, using GT vision stereo microscope (GXM-XTL3T101) for further analysis. After imaging, some excised scaffolds were prepared for histological sectioning and haematoxylin and eosin staining (H&E). Scaffolds were processed, embedded in paraffin wax and sectioned using a standard rotary microtome into 4-µm-thick sections. After de-paraffinising using xylene and rehydrating sections, slides were dipped in Shandon™ Gill™ Hematoxylin (Thermo Fisher Scientific, Loughborough, UK) for 10 min, followed by a warm tap water wash for another 10 min. Sections were then stained with Thermo Scientific™ Shandon™ Eosin Y Cytoplasmic counterstain (Thermo fisher scientific, Loughborough, UK) for 4 min followed by dehydration, clearing, and mounting with cover slips for imaging. Sections were imaged using 10× magnification and then stitched using Microsoft Image Composite Editor (ICE) software.

Quantification of vascularised scaffolds {#section9-2041731420901621}
----------------------------------------

Stereo microscope images of the scaffolds were processed using the 'vessel-analysis' plug-in, in the ImageJ software (NIH). Images were first automatically converted into binary images and then the vascular density analysis function was applied. The vascular density was calculated relative to the scaffold size since some biomaterials shrink by the end of the assay. The software automatically calculates the vascular density normalised to the area of the scaffold. Bifurcation points were counted in each image using ImageJ 'counter' function by digitally selecting the number of branch points seen in the vasculature within a given scaffold.

Statistical analysis {#section10-2041731420901621}
--------------------

GraphPad Prism 7 was used to analyse data. Three scaffolds were analysed per sample tested, and the data are presented as mean ± standard error of the mean (SE). A non-parametric Kruskal--Wallis test was used to compare the differences in vascular density and bifurcation points for each biomaterial tested. A value of *p* \< 0.05 was considered significant.

Results {#section11-2041731420901621}
=======

CAM assay method optimisation {#section12-2041731420901621}
-----------------------------

In this study, we modified and optimised the *ex ovo* CAM assay method previously reported in the literature using a glass-cling film set-up.^[@bibr13-2041731420901621],[@bibr23-2041731420901621],[@bibr27-2041731420901621]^ To increase the survival of the embryos in *ex ovo* conditions, we added AM solution on the developing CAM. Dohle et al.^[@bibr13-2041731420901621]^ reported an improved method of *ex ovo* cultures, which allows the survival of embryos to be over 50%. In our hands, using methods similar those reported by Dohle et al., we observed the survival rate to be \~44%. We further optimised their protocol by the addition of antimicrobial solution to prevent contamination and by using our proposed glass-cling film set-up to avoid trauma to the embryo. Using our proposed method, we repeatedly observed a significant improvement in the survival rate of embryos, which repeatedly exceeded 60%. Therefore, we present a new approach to the traditional *ex ovo* CAM assays with improved embryo survival rates. Furthermore, for the excision of biomaterials from the CAM, we used a novel method of, first, cryotherapy and, second, fixation of the entire CAM using 4% PFA prior to excision of the scaffold. This prevented excessive bleeding from the surrounding vessels ([Figure 4](#fig4-2041731420901621){ref-type="fig"}).

![Data for optimised *ex ovo* method. (a) Survival rate of embryos using the new method (+AM solution) was significantly greater (*p* = 0.0093; unpaired *t*-test) than the previously published method (--AM solution). Data are presented as mean ± SE in each case. (b) Representative images are shown of micro-PCL biomaterial excised without fixation (--4% PFA) and with fixation (+4% PFA). Yellow arrows indicate the areas of excessive bleeding which are absent in the biomaterial excised after fixation.](10.1177_2041731420901621-fig4){#fig4-2041731420901621}

Biomaterial composition and structure {#section13-2041731420901621}
-------------------------------------

Using our proposed method, we examined a wide variety of biomaterials categorised as natural, synthetic, natural/synthetic and natural/natural polymers ([Figure 5](#fig5-2041731420901621){ref-type="fig"} and [Table 1](#table1-2041731420901621){ref-type="table"}). The SEM images show the differences in the structure of the different biomaterials. Within every category of biomaterial composition tested, each biomaterial further represented a range of pore sizes referred to as the GPS ([Figure 6](#fig6-2041731420901621){ref-type="fig"}). For example, macro-PCL has the majority of pores over 120 µm, in addition to the pores in the size range between 0 and 59 µm. Silicone (in the same category) showed the majority of pores to be between 20 and 39 µm, with pores also in the range of 0--19 µm and 60--79 µm. Only 6% of the pores were over 120 µm for elastin, with a majority in the 80--99 µm range (in the natural biomaterial category), whereas at least 21% of the pores in collagen (in the same category) were over 120 µm, with a majority in the range of 20--39 µm. The GPS is a consequence of the fabrication process of natural polymers, whereas for synthetic polymers such as PCL, electrospinning method was used, enabling a controllable pore size range. The overall porosity is an indicator of the total void space within a biomaterial. A variation in the overall porosity of biomaterials was observed ([Table 2](#table2-2041731420901621){ref-type="table"}). The GPS, together with overall porosity, is an important indicator of the porous structure of the biomaterial.

![Representative SEM images of the biomaterials. The SEM results showed the structural variation in porosity, pore size and the general architecture of the scaffold.](10.1177_2041731420901621-fig5){#fig5-2041731420901621}

![The GPS of the biomaterials tested. Doughnut-pie charts revealed a wide range of pore sizes within the biomaterials tested as indicated by the different colours. The lighter the colour, the greater the percentage of larger pores. All the biomaterials tested were composed of both micro-pores and macro-pores (pores over 100 µm).](10.1177_2041731420901621-fig6){#fig6-2041731420901621}

###### 

Percentage porosity of the biomaterials tested.

![](10.1177_2041731420901621-table2)

  Composition category   Scaffold                                   Porosity (%)
  ---------------------- ------------------------------------------ ------------------------------------------
  Natural                Collagen                                   56.8 ± 2.08
  Fibrin                 77.17 ± 1.19                               
  Elastin                33.54 ± 1.59                               
  Synthetic              Micro-PCL                                  80.78 ± 0.92
  Macro-PCL              93.79 ± 0.94                               
  Silicone               2.98 ± 0.15                                
  Natural/Synthetic      Integra^®^                                 90.02 ± 1.98^[@bibr28-2041731420901621]^
  PCL/Fib                53.18 ± 0.56                               
  PCL/Col                57.64 ± 0.72                               
  Natural/Natural        Fibrin/Alginate                            76.39 ± 2.89^[@bibr29-2041731420901621]^
  Matriderm^®^           90 ± 4.00                                  
  DBM                    62.24 ± 4.38^[@bibr30-2041731420901621]^   

DBM: demineralised bone matrix; PCL: poly-ε-caprolactone.

Comparative angiogenic capacity of various biomaterials {#section14-2041731420901621}
-------------------------------------------------------

The CAM assays showed varying degrees of blood vessel infiltration within the different biomaterials tested ([Figure 7](#fig7-2041731420901621){ref-type="fig"}). Blood vessels penetrate from the edges of the biomaterial towards the centre of the biomaterial, and infiltration of vessels was noted throughout the depth of the biomaterial. Blood vessel infiltration was seen to a greater extent in VEGF-soaked discs (positive control) compared to PBS-soaked discs (negative control). His-tology sections corroborated the observation that the blood vessel infiltrated within the biomaterial ([Figure 8](#fig8-2041731420901621){ref-type="fig"}). Blood vessels were observed in all the scaffolds tested except silicone where no blood vessels were seen to infiltrate the scaffold. In all the other biomaterials, vascularisation was seen at varying extents depending on the composition and porosity of the individual biomaterial.

![Representative stereo microscope and binary images of the biomaterials tested. (a) Differences were observed in the vascular infiltration of the different biomaterials tested as indicated by the growth of blood vessels (in red) within these biomaterials. It must be noted that these scaffolds were inverted, so the blood vessel infiltration is observed from the bottom of the biomaterial. Scale bar = 1 mm. (b) The edges of the biomaterial can be easily identified in the binary images where the scaffold itself is shown in white over a black background with blood vessels within the biomaterial shown in black. (c) Controls of VEGF-soaked (+ve) and PBS-soaked (--ve) filter discs showing differences in blood vessel infiltration, with positive control showing a significantly higher (*p* = 0.02; unpaired *t*-test) vascular density than the negative control. Data are presented as mean ± SE.](10.1177_2041731420901621-fig7){#fig7-2041731420901621}

![Representative H&E-stained images of biomaterials. The histology images show the presence of blood vessels within the biomaterial. Yellow arrows point to the blood vessels; CAM refers to the CAM tissue surrounding the biomaterial and BM refers to the biomaterial.](10.1177_2041731420901621-fig8){#fig8-2041731420901621}

The quantification of binary images allowed a more detailed comparison of the biomaterials ([Figure 9](#fig9-2041731420901621){ref-type="fig"}). Fibrin, a pro-angiogenic protein,^[@bibr31-2041731420901621],[@bibr32-2041731420901621]^ had the highest amount of vascularisation as seen in the stereo microscopic images, either as a monomeric biomaterial (Fibrin) or as a composite, combined with either a natural (Fibrin/Alginate) or a synthetic polymer (PCL/Fib). Within the natural polymers, fibrin showed the highest amount of vascularisation and bifurcation points compared to collagen and elastin. However, these differences were only significant for vascular density between collagen and fibrin and not for elastin. For synthetic polymers, both macro- and micro-PCL showed similar vascular density; however, macro-PCL showed a greater number of bifurcation points. This may be due to the presence of many macro-pores, which allows the new capillaries to bifurcate more freely than in the micro-PCL scaffolds. This difference, however, was not significant. For the natural/synthetic composite biomaterials, PCL/Fib showed a greater vascular density compared to Integra^®^, although not significantly greater. Furthermore, PCL/Fib showed fewer bifurcation points than PCL/Col. The vessels within fibrin-based biomaterials appeared relatively thick compared to the vessels in other biomaterials, covering a large surface area, which could be due to the pro-angiogenic capacity of fibrin.^[@bibr31-2041731420901621],[@bibr32-2041731420901621]^ Fibrin/Alginate and DBM, within the natural/natural composite biomaterials, showed greater vascular density and bifurcation points compared to Matriderm^®^, although these differences were only significant for bifurcation points. Individual significant differences for vascular density and bifurcation points are listed in [Tables 3](#table3-2041731420901621){ref-type="table"} and [4](#table4-2041731420901621){ref-type="table"}.

![Vascular density and bifurcation points for each biomaterial. (a) Data for vascular density and bifurcation points corroborated the stereo microscope images. Overall, fibrin-based, monomeric or composite scaffolds showed better vascular infiltration than any other biomaterial. (b) Bifurcation point data showed a similar trend to vascular density data, with the exception of PCL/Fib and Matriderm^®^ showing fewer bifurcation points. Data are presented as mean ± SE. Statistical significance of both graphs is listed in [Tables 3](#table3-2041731420901621){ref-type="table"} and [4](#table4-2041731420901621){ref-type="table"}.](10.1177_2041731420901621-fig9){#fig9-2041731420901621}

###### 

Statistically significant values for biomaterial vascular density.

![](10.1177_2041731420901621-table3)

  ------------------------------- ------------------------------------------------------------ --------
  Collagen vs Fibrin              [\*](#table-fn4-2041731420901621){ref-type="table-fn"}       0.0481
  Collagen vs Fibrin/Alginate     [\*](#table-fn4-2041731420901621){ref-type="table-fn"}       0.0300
  Fibrin vs Macro-PCL             [\*](#table-fn4-2041731420901621){ref-type="table-fn"}       0.0272
  Fibrin vs Silicone              [\*\*](#table-fn4-2041731420901621){ref-type="table-fn"}     0.0019
  Elastin vs Fibrin/Alginate      [\*](#table-fn4-2041731420901621){ref-type="table-fn"}       0.0439
  Macro-PCL vs Fibrin/Alginate    [\*](#table-fn4-2041731420901621){ref-type="table-fn"}       0.0163
  Micro-PCL vs Fibrin/Alginate    [\*](#table-fn4-2041731420901621){ref-type="table-fn"}       0.0330
  Silicone vs PCL/Fib             [\*\*](#table-fn4-2041731420901621){ref-type="table-fn"}     0.0059
  Silicone vs PCL/Col             [\*\*](#table-fn4-2041731420901621){ref-type="table-fn"}     0.0075
  Silicone vs Fibrin/Alginate     [\*\*\*](#table-fn4-2041731420901621){ref-type="table-fn"}   0.0010
  Silicone vs Matriderm^®^        [\*\*](#table-fn4-2041731420901621){ref-type="table-fn"}     0.0094
  Silicone vs DBM                 [\*\*](#table-fn4-2041731420901621){ref-type="table-fn"}     0.0047
  Integra^®^ vs Fibrin/Alginate   [\*](#table-fn4-2041731420901621){ref-type="table-fn"}       0.0481
  ------------------------------- ------------------------------------------------------------ --------

DBM: demineralised bone matrix; PCL: poly-ε-caprolactone.

*p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.

###### 

Statistically significant values for biomaterial bifurcation points.

![](10.1177_2041731420901621-table4)

  --------------------------------- ------------------------------------------------------------ --------
  Collagen vs Silicone              [\*](#table-fn6-2041731420901621){ref-type="table-fn"}       0.0146
  Fibrin vs Micro-PCL               [\*\*](#table-fn6-2041731420901621){ref-type="table-fn"}     0.0075
  Fibrin vs Silicone                [\*\*](#table-fn6-2041731420901621){ref-type="table-fn"}     0.0013
  Fibrin vs Matriderm^®^            [\*](#table-fn6-2041731420901621){ref-type="table-fn"}       0.0117
  Elastin vs Silicone               [\*](#table-fn6-2041731420901621){ref-type="table-fn"}       0.0363
  Macro-PCL vs DBM                  [\*](#table-fn6-2041731420901621){ref-type="table-fn"}       0.0314
  Micro-PCL vs PCL/Col              [\*](#table-fn6-2041731420901621){ref-type="table-fn"}       0.0346
  Micro-PCL vs Fibrin/Alginate      [\*\*](#table-fn6-2041731420901621){ref-type="table-fn"}     0.0075
  Micro-PCL vs DBM                  [\*\*](#table-fn6-2041731420901621){ref-type="table-fn"}     0.0025
  Silicone vs PCL/Col               [\*\*](#table-fn6-2041731420901621){ref-type="table-fn"}     0.0079
  Silicone vs Fibrin/Alginate       [\*\*](#table-fn6-2041731420901621){ref-type="table-fn"}     0.0013
  Silicone vs DBM                   [\*\*\*](#table-fn6-2041731420901621){ref-type="table-fn"}   0.0004
  Integra^®^ vs DBM                 [\*](#table-fn6-2041731420901621){ref-type="table-fn"}       0.0381
  Fibrin/Alginate vs Matriderm^®^   [\*](#table-fn6-2041731420901621){ref-type="table-fn"}       0.0117
  Matriderm^®^ vs DBM               [\*\*](#table-fn6-2041731420901621){ref-type="table-fn"}     0.0041
  --------------------------------- ------------------------------------------------------------ --------

DBM: demineralised bone matrix; PCL: poly-ε-caprolactone.

*p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.

Discussion {#section15-2041731420901621}
==========

The *ex ovo* method presented in this study is to the best of our knowledge the most optimised method for conducting CAM assays, with embryo survival rate exceeding 60%. Although in the early 1980s a study conducted by Dunn et al.^[@bibr33-2041731420901621]^ reported an embryo survival rate exceeding 80%, they used a highly sophisticated method limited by the need for significant expertise and complicated machinery in the lab to perform the experiments. Similarly, in 1974, Auerbach et al.^[@bibr34-2041731420901621]^ used the Petri dish method for *ex ovo* cultures; however, they reported a loss of 50% of the embryos in the first 3 days of incubation. Contamination post *ex ovo* is one of the main reasons for embryonic death in addition to trauma caused from the hard surface of the Petri dish. In our method, we use a simple glass-cling film set-up which can be easily replicated by other researchers, minimising trauma to the embryo. Furthermore, we used a crack open technique without the need for opening the egg using a jigsaw or cut-off wheel as previously reported.^[@bibr21-2041731420901621],[@bibr27-2041731420901621]^ A recent comprehensive study by Mangir et al.^[@bibr23-2041731420901621]^ also reported on a step-by-step protocol for conducting *ex ovo* CAM assays to assess a biomaterial's angiogenic response and biocompatibility. They used antibiotics in a weighing boat set-up and observed a survival rate of 68% by an intermediate user compared to over 80% by an experienced user. In our study, we did not compare antibiotic solution in a weighing boat set-up due to the trauma associated with the hard surface of the weighing boat compared to the soft cling film. Moreover, for a beginner using their method, the survival rates were around 25%, similar to what we observed in our labs. However, using our glass-cling film set-up, a new user in our lab was able to achieve a survival rate of over 60%. This method is safe, time-efficient and results in a higher survival rate of the embryos.

The second aim of this study was to further report the suitability of our optimised *ex ovo* method in the screening of biomaterials to select candidates for further development. We did this by testing the angiogenic properties (i.e. vascular density, number of bifurcation points and presence of blood vessels within the biomaterial) of a wide range of biomaterials intended for various hard and soft tissue applications using our *ex ovo* CAM method as a readout. The biomaterials used in this study differ in composition and structure, and therefore, a variety of angiogenic capacities would be expected. Data presented in this study did indeed show that a biomaterial's composition and structure can have a significant effect on its angiogenic capacity. Various studies have previously suggested that the porous architecture of a biomaterial plays an important role in its revascularisation *in vivo*.^[@bibr35-2041731420901621][@bibr36-2041731420901621]--[@bibr37-2041731420901621]^ It has also been shown that the composition of the biomaterial will affect vascularisation *in vivo*.^[@bibr38-2041731420901621]^ However, there is currently no consensus about the best combination of biomaterial composition and porosity for successful angiogenesis *in vivo.* Previous studies have utilised *in ovo* and *ex ovo* CAM assays to examine angiogenesis and regenerative capacities of biomaterials such as hyaluronic acid--based scaffolds, silk fibroin scaffolds and other natural and synthetic polymers.^[@bibr39-2041731420901621][@bibr40-2041731420901621]--[@bibr41-2041731420901621]^ A study by Keshaw et al.^[@bibr40-2041731420901621]^ showed that using an *in ovo* CAM assay, a significant increase in blood vessel infiltration was seen in collagen spheres compared to PCL spheres. However, a major drawback of the *in ovo* studies is that it does not allow a direct comparison between multiple samples as only one sample can be placed on the CAM at a time. In our study, we were able to compare up to six different scaffolds on the same CAM.

In terms of the results observed, fibrin-based materials showed the best growth of blood vessels. This was expected as fibrin is known to be pro-angiogenic in nature.^[@bibr31-2041731420901621],[@bibr32-2041731420901621]^ PCL/Fib, however, showed a lower number of bifurcation points compared to fibrin/alginate, as well as fibrin on its own. Bifurcation points are reflective of the vessel sprouting phase of the angiogenesis process. During angiogenesis, pre-existing blood supply leads to vascular sprouting that subsequently develops into mature blood vessels. The sequential events that take place during angiogenesis are not fully understood, but it is generally believed that angiogenic sprouting occurs before mature vessel formation.^[@bibr42-2041731420901621]^ Therefore, it can be speculated that fibrin being pro-angiogenic leads to a rapid angiogenic response within these biomaterials where mature vessel formation was seen in all fibrin-based biomaterials as evident by the presence of thick vessels ([Figure 3](#fig3-2041731420901621){ref-type="fig"}). However, perhaps due to monomeric fibrin scaffold and fibrin/alginate scaffold constituting greater porosity than PCL/Fib, a greater number of bifurcation points were seen in the former two scaffolds. This suggests that while the biomaterial is composed of a pro-angiogenic protein, which encourages infiltration of blood vessels, it may not encourage further blood vessel sprouting due to the low porosity of the biomaterial. Our findings are consistent with previously published studies that suggest the presence of macro-pores and higher porosity is beneficial for the growth of blood vessels *in vivo*.^[@bibr35-2041731420901621],[@bibr43-2041731420901621],[@bibr44-2041731420901621]^ However, just having a higher porosity is insufficient for adequate angiogenesis. For instance, macro-PCL biomaterial used in this study constituted 87% of the pores in the macro-pore range with an overall porosity of 93.79 ± 0.94%, yet showed poor angiogenic capacity which could be attributed to the polymeric composition, as PCL alone does not favour the growth of endothelial cells.^[@bibr45-2041731420901621]^ Similarly, Integra^®^, a commercially available clinical scaffold used for the treatment of full-thickness skin wounds, constituted an overall porosity of 90.02 ± 1.98%, yet showed limited vascularisation. This may be, again, due to the composition of the biomaterial, particularly the glycosaminoglycan content in Integra^®^, which has been previously shown to inhibit angiogenesis.^[@bibr46-2041731420901621][@bibr47-2041731420901621]--[@bibr48-2041731420901621]^ *In vivo* studies^[@bibr49-2041731420901621],[@bibr50-2041731420901621]^ in mice have shown that Integra^®^ exhibits between 3% and 17% blood vessel area, which is similar to the results reported using the *ex ovo* CAM method described in this study. Moreover, Integra^®^ when combined with a fibrin sealant shows vascularity of over 20%.^[@bibr50-2041731420901621]^ These studies corroborate the finding presented in this article with increased angiogenesis seen in fibrin-based biomaterials.

The synthetic materials, in general, showed poor angiogenesis. It may be speculated that since synthetic materials lack the natural extracellular matrix (ECM) molecules, they would not encourage vascularisation. Previous studies have enhanced the ability of PCL scaffolds to encourage angiogenesis by coating with heparin and VEGF as well as combining PCL with other polymers.^[@bibr51-2041731420901621][@bibr52-2041731420901621]--[@bibr53-2041731420901621]^ It is also well established that synthetic biomaterials should be used in combination with the natural ECM molecules such as collagen and fibrin in order to enhance their regenerative potential,^[@bibr54-2041731420901621],[@bibr55-2041731420901621]^ with the exception of certain synthetic materials including bioactive bioglasses, which are known to stimulate angiogenesis *in vivo*.^[@bibr56-2041731420901621]^ From the data obtained in this study, it is difficult to warrant any further conclusions on synthetic scaffolds as the choice of the synthetic materials used in this study was quite limited, although both PCL and silicone are widely used for medical applications.^[@bibr57-2041731420901621],[@bibr58-2041731420901621]^ Further work needs to be conducted on a wider range of synthetic biomaterials to make further conclusions about their angiogenic capacity.

Adding a natural polymer (fibrin or collagen) to synthetic scaffolds significantly improved their ability to undergo vascularisation, even when the porosity remains lower than 70%.^[@bibr43-2041731420901621]^ Collagen and fibrin are the two key ECM molecules that have previously been shown to favour angiogenesis.^[@bibr59-2041731420901621][@bibr60-2041731420901621]--[@bibr61-2041731420901621]^ These findings suggest that when a biomaterial is composed of composites containing a pro-angiogenic material like fibrin or a natural ECM molecule like collagen type I, the porosity does not have a significant effect on the overall angiogenic capacity of the biomaterial so long as it allows vascular infiltration.

In conclusion, we utilised an optimised *ex ovo* CAM assay to screen a variety of biomaterials commonly used in tissue engineering and biomedical applications. From our results, the presented *ex ovo* CAM assay would be effective for pre-screening biomaterials prior to *in vivo* testing as evident by the variation observed in the angiogenic capacity of the 12 different biomaterials tested. However, further studies are required to confirm that the results are consistent with the *in vivo* situation. Furthermore, in-depth histological evaluation of a selected biomaterial after excision from the CAM could be performed to further evaluate the angiogenic response of the biomaterials after placement on the CAM. However, our study aimed at performing an initial screening of a variety of biomaterials to see whether our proposed method could detect differences between the materials tested, which our results showed it did. The angiogenic response observed on the CAM was as expected, with fibrin-based scaffolds showing the greatest amount of vascularisation. Furthermore, interesting interactions were observed when the effect of angiogenesis was attributed to the variation in porosity and composition. To the best of our knowledge, we are the first group to test such a large number of scaffolds on a very sensitive *ex ovo* angiogenesis assay. In conclusion, this study has demonstrated that a biomaterial's composition and porosity have a direct effect on its intrinsic angiogenic capacity, and this effect can be evaluated using an *ex ovo* CAM assay such as the one described here.
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